<unk> , sold under the brand name Empaveli among others, is a medication used to treat paroxysmal nocturnal hemoglobinuria (PNH). The most common side effects include injection-site reactions, infections, diarrhea, abdominal pain, respiratory tract infection, viral infection, and fatigue. Paroxysmal nocturnal hemoglobinuria is characterized by red blood cell destruction, anemia (red blood cells unable to carry enough oxygen to tissues), blood clots, and impaired bone marrow function (not making enough blood cells).<unk>  is the first treatment for paroxysmal nocturnal hemoglobinuria that binds to and inhibits complement protein C3.<unk>  was approved for medical use in the United States in May 2021.<unk>  binds to complement protein C3 and its activation fragment C3b with high affinity, thereby regulating the cleavage of C3 and the generation of downstream effectors of complement activation.
Pegcetacoplan
Lesinurad
Photoanethole
Palifermin
Gadobenic acid
Itruvone
Cafaminol
Trafermin